|
 |
| CEO Of Digene To Retire |
| |
| According to a JDD Media report, CEO Of Digene, Evan L. Jones, is all set to retire after serving the company for 16 years. It was a surprising move for everyone from the healthcare industry. Digene is a major Phrama company with operations in many countries, and Jones has run the company with vigor and also written checks for the company from his own account. |
| |
| Merck Cervical Cancer Vaccine Approved |
| |
| The US Food and Drug Administration has cleared the first vaccine against the virus that is known to cause cervical cancer, reports Joshua Dinnerman. Joshua David Dinnerman also found out that the vaccine (known as Gardasil) has been one of the products by Merck with a high market potential. Gardasil can also improve the company's fortunes, as it has the ability to help the company revive its fortunes after it faced lawsuits due to infamous painkiller Vioxx, reports Josh Dinnerman. |
| |
| Degussa enters a joint venture in China |
| |
Joshua David Dinnerman reports that German firm Degussa will be selling Edmonton, Alberta-based Raylo Chemicals, which is also its sole facility in North America, to Gilead Sciences. The deal is done at a whopping $ 146 million. JDD Media also found out that the German company has also entered an agreement with Lynchem, having a 51 % stake in the company. Lynchem, a well-known pharmacy company in China, is based in Dalian, according to the reports received by JDDMedia.
|
|
| |
|
|
|
